trial · primary record
Azacitidine
Acute Myeloid Leukemia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 147 |
| Primary completion | 2029-05-15 |
| Primary endpoint | Rate of measured residual disease (MRD) negative complete remission (CR) |
| Registry ID | NCT06317649 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:20.599Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06317649
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.